Lukang Pharmaceutical forecasts 60% profit decline for H1

Shandong Lukang Pharmaceutical anticipates net profit of 102-122 million yuan for the first half of 2025, down 59-66% year-on-year. The decline stems from a large asset disposal gain of 156 million yuan in the same period last year from transferring land use rights.

Excluding non-recurring items, the company expects net profit of 95-108 million yuan, up 3-17% year-on-year, reflecting improved operational performance through enhanced management and optimized production processes.